Fun fact, Tysabri was withdrawn from the market when some cases of a rare cancer were reported. It was introduced back only after lobbying by patient groups who insisted they’d take the small risk for the amazing QOL improvement from this drug.

Do you mean PML? That’s not a cancer, but a viral infection.

Right? 10 or 15 years ago there were litterally no drugs that changed the course of MS. But then Tysabri came along and suddenly things changed for RRMS. And now Ocrelizumab seems to work for both RR and progressive MS. It IS some kind of miracle.

Absolutely, though the cost of antibody drugs (even biosimilars) leaves a lot to be desired. We have ways to go in that regard.